Innova Captab Limited has informed the Exchange regarding a press release dated May 19, 2025, titled "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ( SEBI LODR Regulations ), we are enclosing herewith the Press Release issued by the Company on the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2025. ".
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Innova Captab Limited, an integrated pharmaceutical company, reported strong FY25 results with revenue from operations growing 15% year-on-year to ₹1,243.7 crores (vs ₹1,081.3 crores in FY24). Full-year PAT jumped 36% to ₹128.3 crores, and EBITDA rose 19% to ₹198.2 crores, with EBITDA margin improving 50 basis points to 15.9% and PAT margin improving 160 basis points to 10.3%. For Q4 FY25 alone, revenue grew 20% to ₹314.7 crores and EBITDA grew 17% to ₹51.1 crores, while PAT rose a modest 3% to ₹29.6 crores due to higher depreciation and finance costs from the newly commissioned Kathua, Jammu plant. The company highlighted deepened CDMO partnerships, expanded product portfolio, exports to 30 countries, and a new R&D facility being set up in Panchkula, Haryana.
The 36% jump in full-year PAT and 50 bps margin expansion signal strong operational leverage and improving profitability, likely to be viewed positively by investors. However, the muted Q4 PAT growth (only 3%) due to new plant costs may temper near-term excitement, though the long-term growth story from the Kathua facility's scaled production looks intact.